Can Enliven Therapeutics, Inc. (ELVN) Climb 75.66% to Reach the Level Wall Street Analysts Expect?

Group 1 - Enliven Therapeutics, Inc. (ELVN) shares have increased by 8.2% over the past four weeks, closing at $23.34, with a mean price target of $41 indicating a potential upside of 75.7% [1] - The mean estimate consists of eight short-term price targets with a standard deviation of $6.74, where the lowest estimate of $33.00 suggests a 41.4% increase, and the highest estimate of $52.00 indicates a potential surge of 122.8% [2] - Analysts show strong agreement in revising earnings estimates higher, which correlates with potential stock price increases, as the Zacks Consensus Estimate for the current year has risen by 4.6% over the past month [11][12] Group 2 - ELVN holds a Zacks Rank 2 (Buy), placing it in the top 20% of over 4,000 ranked stocks based on earnings estimates, indicating a strong potential for upside [13] - While consensus price targets may not be reliable indicators of the extent of gains, they can provide a directional guide for price movement [14]